Treating obesity: Lost cause or new opportunity?

Canadian Family Physician

Volumn 46, Issue SEPT, 2000, Pages 1806-1813

  Plourde, G ^a  

^a Office 104   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMPHETAMINE; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BARIATRIC SURGERY; BEHAVIOR THERAPY; CONTINUING EDUCATION; DIET THERAPY; DRUG INDUCED DISEASE; EXERCISE; HUMAN; OBESITY; PULMONARY HYPERTENSION; REVIEW; RISK BENEFIT ANALYSIS; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; BEHAVIOR THERAPY; BODY WEIGHT; COMBINED MODALITY THERAPY; COMORBIDITY; DIET, REDUCING; EVIDENCE-BASED MEDICINE; EXERCISE THERAPY; HUMAN; MEDICAL HISTORY TAKING; OBESITY; PHYSICAL EXAMINATION; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 0033825305     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examinations surveys, 1960 to 1991
2. Obesity in Canada: A descriptive analysis. Canadian Heart Health Surveys Research Group
3. Actual causes of death in United States
4. The cost of obesity in Canada
5. Genetic and the molecular basis of obesity
6. Discrepancy between reported and actual calorie intake and exercise in obese subjects
7. Validity of reported calorie intake
8. A public health approach to the problem of obesity
9. Changes in energy expenditure resulting from altered body weight
10. An adoption study of human obesity
11. The response to long-term overfeeding in identical twins
12. Genetics of body fat content
13. Classification of obese patients and complications related to the distribution of surplus fat
14. Portal adipose tissue as a generator of risk factors for cardiovascular disease and diabetes
15. Beneficial health effects of modest weight loss
16. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity
17. Effect of degree of weight loss on health benefits
18. Reducing primary risk factors by therapeutic weight loss
19. Obesity and hypertension, cardiovascular response of weight reduction
20. The treatment and prevention of obesity: A systematic review of the literature
21. Weight cycling
22. Gastrointestinal surgery for severe obesity: Consensus Development Conference statement
23. Evidence for success of behavior modification in weight loss and control
24. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects
25. In search of how people change. Applications to addictive behaviors
26. Responsible and irresponsible use of very-low-calorie diets in the treatment of obesity
27. Long-term exercise training with constant energy intake. 1: Effect on body composition and selected metabolic variables
28. Update on the pharmacotherapy of obesity
29. Appetite suppressants. A review
30. Appetite suppressants as adjuncts in the treatment of obesity
31. INDEX (international dexfenfluramine study) as a model for long-term pharmacotherapy of obesity in the 1990s
32. Long-term weight control study. V.(weeks 190-210). Follow-up of participants after cessation of medication
33. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group
34. Sibutramine: A novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine
35. Sibutramine - A review of the pharmacology of a novel antiobesity drug
36. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group
37. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study
38. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial
39. The effects of health beliefs on weight loss in individuals at high risk for NIDDM
40. A ten-year follow-up of weight change in severely obese subjects treated in a combined behavioural modification program
41. Impact of dietary fat content and fat oxidation on energy intake in humans
42. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women
43. Evidence for success of exercise in weight loss and control
44. Pharmacotherapy for obesity: Do the benefits outweigh the risks?
45. Dr Curfman replies
46. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults
47. Relation of weight loss to changes in serum lipids and lipoproteins in obese women
48. Obesity, weight loss and prognosis in type II diabetes
49. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years